HCM
PRTK

Highbridge Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Highbridge Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-60,500
Closed -$617K – 936
2018
Q2 		$617K Buy
+60,500
New +$685K 0.01% 548

Other funds holding PRTK

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Highbridge Capital Management's PRTK Position: Q4 2022 in Review

Highbridge Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2022, closing a stake of 42,154 shares — an estimated $108K sold.

Highbridge Capital Management first reported a position in PRTK in Q3 2016 and held it in 6 quarters. The position peaked at $5.29M in Q3 2017. 76 funds tracked by Wall St. Rank hold PRTK as of Q4 2022.

  • Highbridge Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Highbridge Capital Management sold 42,154 Paratek Pharmaceuticals, Inc. shares in Q4 2022, an estimated $108K.
  • Highbridge Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2016 and held it in 6 quarters.
  • Highbridge Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $5.29M in Q3 2017.
  • 76 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2022.

Based on Highbridge Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.